Information Provided By: 
Fly News Breaks for May 31, 2018
CRIS
May 31, 2018 | 13:33 EDT
SunTrust analyst Peter Lawson notes that Curis announced that fimepinostat received fast track status from the FDA. The analyst believes this signals that the FDA is supportive of moving forward with the drug. Lawson reiterates a Buy rating on the shares, while raising his price target on the stock to $18.00 from $17.50 post reverse split.
News For CRIS From the Last 2 Days
There are no results for your query CRIS
